Reviewer’s report

Title: Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line Helicobacter pylori eradication therapy in patients allergic to penicillin

Version: 4 Date: 02 Jul 2019

Reviewer: Chao-Hung Kuo

Reviewer's report:

Thank you for your efforts on the added paragraph according to my suggestions. The modified table and discussion content make your manuscript more complete.

The table 3 showed univariate and multi-variates data with p value and this makes readers to get more understanding of the significance of your result. Also, you make clear that all patients are Tx-naïve and emphasize the lack of previous antibiotics history in your limitation part. That explanation makes your result more realistic.

However, one minor revision needs to be done. Your new references 9-12 are about the eradications rates of patients with allergy to penicillin. However, the references are from the same group, Gisbert JP from Spain. Could you please provide the reference originating from mainland China? the local data is more convincing and more realistic when it comes to Hp eradication.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.
I agree to the open peer review policy of the journal